Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Pharming receives funding for development of new treatments for premature ageing diseases

29 Jan 2008 - Pharming Group NV announced that its wholly owned subsidiary DNage will head a collaborative Research and Development effort to identify novel biomarkers and therapeutic targets, and to develop therapeutics for the treatment of premature ageing diseases. The consortium has been granted a SenterNovem subsidy of EUR 905.000 for a period of three years.
 
Under an International Innovation Subsidy granted by SenterNovem, an agency of the Dutch Ministry of Economic Affairs, DNage has initiated a project with the Eberhard Karls University in Tubingen Germany, and Pyxis Discovery BV, to design new drug development tools aimed at discovery of new therapeutics to treat (premature) ageing diseases. In addition, DNage will collaborate with the Leiden University Medical Center to identify unique biomarkers of such diseases that will facilitate the clinical development of new therapies.
 
The Company has filed several patent-applications based on the work performed in this field during the past few years. It expects that this additional funding will accelerate its drug development program which involves the start of a clinical program later this year to test a new product (Prodarsan®) for the treatment of premature ageing diseases.